Solid Biosciences (SLDB) PT Lowered to $17 at Chardan Capital Markets, Keeps 'Buy' Rating Amid SGT-001 Data
Tweet Send to a Friend
Chardan Capital Markets analyst Geulah Livshits lowered the price target on Solid Biosciences (NASDAQ: SLDB) to $17.00 (from $20.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
